1. Search Result
Search Result
Results for "

pPLCγ1

" in MedChemExpress (MCE) Product Catalog:

77

Inhibitors & Agonists

1

Biochemical Assay Reagents

5

Peptides

20

Inhibitory Antibodies

8

Natural
Products

32

Recombinant Proteins

2

Isotope-Labeled Compounds

15

Antibodies

2

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P1214

    Melanocortin Receptor Cardiovascular Disease
    γ1-MSH is a melanocortin MC3 receptor agonist, with a Ki of 34 nM for the rat MC3 receptor. γ1-MSH displays ~40-fold selectivity over MC4 (Ki=1318 nM) [1].
    γ1-MSH
  • HY-19609
    Calicheamicin
    5+ Cited Publications

    Calicheamicin γ1

    DNA Alkylator/Crosslinker ADC Payload Bacterial Apoptosis Antibiotic Infection Cancer
    Calicheamicin, an antitumor antibiotic, is a cytotoxic agent that causes double-strand DNA breaks. Calicheamicin is a DNA synthesis inhibitor [1]. Calicheamicin is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    Calicheamicin
  • HY-P991027

    CD47 Inflammation/Immunology
    HY-P991027 is an CD47/CLDN18-targeting (H-γ1_L-κ)_(H-γ1_L-κ) type bispecific antibody [1].
    Spevatamig
  • HY-N1773

    Others Cancer
    5,7,3' -tri-O-Methyl (-)-epicatechin (Compound 13) is a phospholipase Cγ1 (PLCγ1) inhibitor. 5,7,3' -tri-o-methyl (-)-epicatechin has a methylene dioxy benzene ring and can express inhibitory activity against PLCγ1. 5,7,3' -tri-O-Methyl (-)-epicatechin can be used in the study of chemotherapy and chemopexic agents for cancer [1].
    5,7,3'-Tri-O-methyl (-)-epicatechin
  • HY-P991036

    GR-1803

    TNF Receptor Inflammation/Immunology
    HY-P991036 is an CD3E/TNFRSF17-targeting H-γ1_L-κ/H-γ1_L-κ type bispecific antibody [1].
    Velinotamig
  • HY-N14490

    Antibiotic Bacterial Infection
    Coumamidine γ1 is a kind of alkaline sugar Cinodine antibiotic, which has broad spectrum antibacterial activity and also has effect on pseudomonas aeruginosa [1].
    Coumamidine γ1
  • HY-P1214A

    Melanocortin Receptor Cardiovascular Disease
    γ1-MSH TFA is a melanocortin MC3 receptor agonist, with a Ki of 34 nM for the rat MC3 receptor. γ1-MSH TFA displays ~40-fold selectivity over MC4 (Ki=1318 nM) [1].
    γ1-MSH TFA
  • HY-P990161

    MHC Inflammation/Immunology Cancer
    Anti-Mouse TCR Vγ1.1/Cr4 Antibody (2.11) is an anti-mouse TCR Vγ1.1/Cr4 IgG monoclonal antibody. Anti-Mouse TCR Vγ1.1/Cr4 Antibody (2.11) can deplete Vγ1 γδ T cells. Anti-Mouse TCR Vγ1.1/Cr4 Antibody (2.11) can be used for research on cancer and inflammation conditions such as mastitis and colon cancer [1] .
    Anti-Mouse TCR Vγ1.1/Cr4 Antibody (2.11)
  • HY-E70796

    AMPK Cancer
    AMPK is an αβγ heterotrimeric serinethreonine kinase activated by decreasing concentrations of adenosine triphosphate (ATP) and increasing AMP concentrations. Biotin-AMPKα2β1γ1 Recombinant Human Active Protein Kinase is obtained by co-expressing AMPKα2, AMPKβ1, and AMPKγ1 proteins and is biotinylated [1].
    Biotin-AMPKα2β1γ1 Recombinant Human Active Protein Kinase
  • HY-E70795

    AMPK Cancer
    AMPK is an αβγ heterotrimeric serinethreonine kinase activated by decreasing concentrations of adenosine triphosphate (ATP) and increasing AMP concentrations. Biotin-AMPKα1β2γ1 Recombinant Human Active Protein Kinase is obtained by co-expressing AMPKα1, AMPKβ2, and AMPKγ1 proteins and is biotinylated [1].
    Biotin-AMPKα1β2γ1 Recombinant Human Active Protein Kinase
  • HY-E70793

    AMPK Cancer
    AMPK is an αβγ heterotrimeric serinethreonine kinase activated by decreasing concentrations of adenosine triphosphate (ATP) and increasing AMP concentrations. Biotin-AMPKα1β1γ1 Recombinant Human Active Protein Kinase is obtained by co-expressing AMPKα1, AMPKβ1, and AMPKγ1 proteins and is biotinylated [1].
    Biotin-AMPKα1β1γ1 Recombinant Human Active Protein Kinase
  • HY-P990972

    EGFR Inflammation/Immunology
    HY-P990972 is an KLRK1/ERBB2-targeting (H-γ1_L-κ)_scFvkh-H-γ1(h-CH2-CH3) type bispecific antibody [1].
    Azerutamig
  • HY-E70787

    AMPK Cancer
    AMPK is an αβγ heterotrimeric serinethreonine kinase activated by decreasing concentrations of adenosine triphosphate (ATP) and increasing AMP concentrations. AMPK α1β1γ1 Recombinant Human Active Protein Kinase is an ortholog of AMPK. AMPK α1β1γ1 Recombinant Human Active Protein Kinase is obtained by co-expressing AMPKα1, AMPKβ1, and AMPKγ1 proteins [1].
    AMPK α1β1γ1 Recombinant Human Active Protein Kinase
  • HY-101649

    TAK-559

    PPAR Cardiovascular Disease
    Imiglitazar (TAK559) is a potent and dual human PPARα and PPARγ1 agonist with EC50 values of 67 and 31 nM.
    Imiglitazar
  • HY-P990021

    Bacterial Others
    Calpurbatug is an immunoglobulin G1 antibody. Calpurbatug has activity with anti-bacterial DNA-binding protein DNABII family and anti-human monoclonal TRL1068 γ1-chain [1].
    Calpurbatug
  • HY-P991700

    Claudin CD3 Cancer
    Lumivatamig is an H-γ1_L-κ-scFvhl dimer-type bispecific antibody targeting CLDN18.2 & CD3E [1].
    Lumivatamig
  • HY-P991016

    PT-217

    CD47 Inflammation/Immunology
    HY-P991016 is an CD47/DLL3-targeting H-γ1_L-κ type bispecific antibody [1].
    Peluntamig
  • HY-P991034

    CD3 Inflammation/Immunology
    HY-P991034 is an EPCAM/CD3E-targeting H-γ1_L-κ-scFvhl dimer type bispecific antibody [1].
    Trevotamig
  • HY-P990903

    CD3 Inflammation/Immunology
    HY-P990903 is an CD3E/CD33-targeting [H-γ1 _ L-κ-scFv heavy -κ]-dimer type bispecific antibody [1].
    Avitotamig
  • HY-P991147

    PD-1/PD-L1 Cancer
    Ledostomig is an immunoglobulin (H-γ1-scFv-L-κ) dimer monoclonal antibody targeting human netrin-5 (NTS5) and programmed death-1 (PD-1). Ledostomig is promising for research of various cancers [1].
    Ledostomig
  • HY-P990980

    CND-106; EMB-06

    TNF Receptor Inflammation/Immunology
    HY-P990980 is an TNFRSF17-targeting [L-κ-H-γ1_[VH-G1(CH1-h)]_Lκ] dimer type humanized antibody [1].
    Cizutamig
  • HY-P991004

    CD47 Inflammation/Immunology
    HY-P991004 is an CD274/CD47-targeting (VH-G1CH1-h)-H-γ1_L-κ-L-κ type bispecific antibody [1].
    Itanistomig
  • HY-P991015

    CD3 Inflammation/Immunology
    HY-P991015 is an KLK2/CD3E-targeting (H-γ1_L-κ)_scFvkh-G1(h-CH2-CH3) type bispecific antibody [1].
    Pasritamig
  • HY-P990905

    SAR-443579

    Interleukin Related Inflammation/Immunology
    HY-P990905 is an IL3RA/NCR1-targeting [(H-γ1-VH-CH1-h_L-κ)_L-κ-h-CH2-CH3] type bispecific antibody [1].
    Bexatamig
  • HY-N0084
    Betulinaldehyde
    5 Publications Verification

    Betulinic aldehyde; Betunal

    Bacterial Infection Cardiovascular Disease Cancer
    Betulinaldehyde (Betunal) Has anti-cancer and anti-staphylococcus aureus activity. Betulinaldehyde Suppressible Akt, MAPK sum STAT3 Signal path, increase self-transfer, Suppression A549 Cellular vitality, increase and transfer. Betulinaldehyde suppresses PLCγ1/Ca 2+/MMP9 signal pathway, has a key effect on vascular plasticity, and is available for cardiovascular disease (CVD) research.
    Betulinaldehyde
  • HY-146672

    Itk Cancer
    ITK inhibitor 6 (compound 43) is a potent and selective ITK inhibitor with IC50s of 4 nM, 133 nM, 320 nM, 2360 nM, 155 nM for ITK, BTK, JAK3, EGFR, LCK, respectively. ITK inhibitor 6 inhibits phosphorylation of PLCγ1 and ERK1/2. ITK inhibitor 6 shows antiproliferative activities [1].
    ITK inhibitor 6
  • HY-P991151

    PD-1/PD-L1 TNF Receptor Cancer
    Opamtistomig is a humanized immunoglobulin (H-γ1-scFv-L-κ) dimer monoclonal antibody targeting human programmed death ligand 1 (PD-L1), CD274 and tumor necrosis factor receptor superfamily member 9 (TNFRSF9). Opamtistomig is promising for research of various solid tumors and hematological malignancies [1].
    Opamtistomig
  • HY-P9991

    TST001

    Gap Junction Protein Cancer
    Osemitamab is an IgG1 antibody targeting to human claudin-18.2. Osemitamab consists of human-Mus musculus monoclonal TST001 γ1-chain, disulfide with human-Mus musculus monoclonal TST001 κ-chain, dimer (ACI). Osemitamab in combination with Capecitabine (HY-B0016) and Oxaliplatin (HY-17371), can be used for G/GEJ cancer study [1] .
    Osemitamab
  • HY-B0700

    BRL 49653 sodium

    PPAR TRP Channel Autophagy Metabolic Disease Inflammation/Immunology
    Rosiglitazone sodium is a potent and selective activator of PPARγ, with EC50s of 30 nM, 100 nM and 60 nM for PPARγ1, PPARγ2, and PPARγ, respectively, and a Kd of appr 40 nM for PPARγ; Rosiglitazone sodium is also an modulator of TRP channels, inhibits TRP melastatin 2 (TRPM2), TRPM3 and activates TRP canonical 5 (TRPC5).
    Rosiglitazone sodium
  • HY-14600
    Rosiglitazone maleate
    Maximum Cited Publications
    143 Publications Verification

    BRL 49653C

    PPAR TRP Channel Autophagy Ferroptosis Metabolic Disease Inflammation/Immunology Cancer
    Rosiglitazone maleate (BRL 49653C) is a potent and selective activator of PPARγ, with EC50s of 30 nM, 100 nM and 60 nM for PPARγ1, PPARγ2, and PPARγ, respectively, and a Kd of appr 40 nM for PPARγ; Rosiglitazone maleate is also an modulator of TRP channels, inhibits TRP melastatin 2 (TRPM2), TRPM3 and activates TRP canonical 5 (TRPC5).
    Rosiglitazone maleate
  • HY-P991149

    TNF Receptor Cancer
    Nesfrotamig is a humanized immunoglobulin (H-γ1-scFv-L-κ) dimer monoclonal antibody targeting human epidermal growth factor receptor 2 (ERBB2) and human tumor necrosis factor receptor superfamily member 9 (TNFRSF9). Nesfrotamig is promising for research of cancers, especially in ERBB2-positive related tumor diseases, such as breast cancer and gastric cancer [1].
    Nesfrotamig
  • HY-14600R

    BRL 49653C (Standard)

    Reference Standards PPAR TRP Channel Autophagy Ferroptosis Metabolic Disease Inflammation/Immunology Cancer
    Rosiglitazone (maleate) (Standard) is the analytical standard of Rosiglitazone (maleate). This product is intended for research and analytical applications. Rosiglitazone maleate (BRL 49653C) is a potent and selective activator of PPARγ, with EC50s of 30 nM, 100 nM and 60 nM for PPARγ1, PPARγ2, and PPARγ, respectively, and a Kd of appr 40 nM for PPARγ; Rosiglitazone maleate is also an modulator of TRP channels, inhibits TRP melastatin 2 (TRPM2), TRPM3 and activates TRP canonical 5 (TRPC5).
    Rosiglitazone maleate (Standard)
  • HY-135799

    Phospholipase Neurological Disease Cancer
    WH-15 is a fluorogenic PLC reporter with Km value of 49; 30, 86.1 µM for PLC-γ1, PLC1, PLC-β2, respectively. WH-15 can be cleaved in a cascade reaction to generate fluorescent 6-aminoquinoline. WH-15 can be used to respond to imaging PLC activity in live cells (Ex/Em = ~344/530 nm) [1].
    WH-15
  • HY-17386S

    Isotope-Labeled Compounds PPAR TRP Channel Autophagy Ferroptosis Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    Rosiglitazone-d3 is the deuterium labeled Rosiglitazone. Rosiglitazone (BRL 49653) is a selective, orally active PPARγ agonist with EC50s of 30 nM, 100 nM and 60 nM for PPARγ1, PPARγ2, and PPARγ, respectively. Rosiglitazone binds to PPARγ with a Kd of approximately 40 nM. Rosiglitazone is also an activator of TRPC5 (EC50=~30 μM) and an inhibitor of TRPM3 [1] .
    Rosiglitazone-d3
  • HY-B1803A

    ICI 136753 hydrochloride

    GABA Receptor Neurological Disease
    Tracazolate (ICI 136753) hydrochloride is a potent GABAA receptor modulator. Tracazolate hydrochloride has selectivity for β3 and potentiates α1β1γ2s (EC50=13.2 μM), α1β3γ2 (EC50=1.5 μM). Tracazolate hydrochloride has the potency (EC50) determined by the nature of the third subunit (γ1-3, δ, ε) within the receptor complex. Tracazolate hydrochloride possesses anxiolytic and anticonvulsant activity [1] .
    Tracazolate hydrochloride
  • HY-178335

    LDLR Wnt CMV Infection
    SGC-CK1γ-1 is a potent and selective probe for the CK1γ subfamily. SGC-CK1γ-1 can inhibit LRP6 phosphorylation levels. SGC-CK1γ-1 can selectively inhibit the CK1γ kinases in living cells and inhibit both WNT signaling and human cytomegalovirus (CMV) replication. SGC-CK1γ-1 can be used for the research of infection [1].
    SGC-CK1γ-1
  • HY-P1531

    Melanocortin Receptor Cardiovascular Disease Metabolic Disease Endocrinology
    γ-1-Melanocyte Stimulating Hormone (MSH), amide is a 11-amino acid peptide. γ-1-Melanocyte Stimulating Hormone (MSH) regulates sodium (Na +) balance and blood pressure through activation of the melanocortin receptor 3 (MC3-R).
    γ-1-Melanocyte Stimulating Hormone (MSH), amide
  • HY-157129

    AMPK Cardiovascular Disease
    AMPK-α1β1γ1 activator 1 (M1) is an acyl glucuronide metabolite of Indole-3-carboxylic Acid-based AMPK activator. AMPK-α1β1γ1 activator 1 can selectively activated human β1 isoforms with an EC50 value of 38.1nM. AMPK-α1β1γ1 activator 1 can direct binding with human AMPK α1β1γ1 isoform. AMPK-α1β1γ1 activator 1 can be used for the research of diabetic nephropathy [1].
    AMPK-α1β1γ1 activator 1
  • HY-151920

    Btk Inflammation/Immunology
    BTK-IN-17 (compound 36R) is a selective and orally activeBTK inhibitor with an IC50 value of 13.7 nM. BTK-IN-17 decreases the expression of p-BTK Y223 and p-PLCγ2 Y1217. BTK-IN-17 shows anti-inflammatory effects [1].
    BTK-IN-17
  • HY-16708A
    ZLN024 hydrochloride
    1 Publications Verification

    AMPK Metabolic Disease
    ZLN024 hydrochloride is an AMPK allosteric activator. ZLN024 directly activates recombinant AMPK α1β1γ1, AMPK α2β1γ1, AMPK α1β2γ1 and AMPK α2β2γ1 heterotrimer with EC50s of 0.42 µM, 0.95 µM, 1.1 µM and 0.13 µM, respectively.
    ZLN024 hydrochloride
  • HY-16708

    AMPK Metabolic Disease
    ZLN024 is an AMPK allosteric activator. ZLN024 directly activates recombinant AMPK α1β1γ1, AMPK α2β1γ1, AMPK α1β2γ1 and AMPK α2β2γ1 heterotrimer with EC50s of 0.42 µM, 0.95 µM, 1.1 µM and 0.13 µM, respectively.
    ZLN024
  • HY-112769
    EX229
    5 Publications Verification

    AMPK Metabolic Disease
    EX229, a Benzimidazole derivative, is a potent and allosteric activator of AMP-activated protein kinase (AMPK), with Kds of 0.06 μM, 0.06 μM and 0.51 μM for α1β1γ1, α2β1γ1 and α1β2γ1 in biolayer interferometry, respectively.
    EX229
  • HY-147038

    AMPK Metabolic Disease
    AMPK activator 8 (compound 2) is an AMP-activated protein kinase (AMPK) activator with EC50s of 11, 27, 4, 2, and 4 nM for rAMPK α1β1γ1, rAMPK α2β1γ1, rAMPK α1β2γ1, rAMPK α2β2γ1, rAMPK α2β2γ3, respectively. AMPK activator 8 can be used for the research of type 2 diabetes [1].
    AMPK activator 8
  • HY-49076

    ROR Cancer
    RORγ inverse agonist 1 is the inverse agonist of RORγ .
    RORγ inverse agonist 1
  • HY-158934

    Cannabichromenquinone

    PPAR Others
    (±)-CBCQ is an oxidative product of cannabichromene, with an EC50 of 14.7 μM for PPAR-γ .
    (±)-CBCQ
  • HY-120270

    AMPK Metabolic Disease
    PF-06679142 (Compound 10) is a potent, orally active AMPK activator with an EC50 of 22 nM against α1β1γ1-AMPK. PF-06679142 can be used for diabetic nephropathy research [1].
    PF-06679142
  • HY-14728S

    Aleglitazar-d2; R1439-d2; RO0728804-d2

    PPAR Others
    Deutaleglitazar (Aleglitazar-d2) is a agonist of dual peroxisome proliferatory activating receptor (PPARα and PPARγ) .
    Deutaleglitazar
  • HY-14817

    PPM 204

    PPAR Metabolic Disease
    Indeglitazar (PPM 204) is an orally available PPAR pan-agonist for all three PPARα, PPARδ and PPARγ .
    Indeglitazar
  • HY-163985

    PROTACs FGFR Apoptosis Cancer
    PROTAC FGFR2 degrader 1 (compound N5) is a PROTAC that effectively targets FGFR2 with DC50 of 6.46 nM, the FGFR2 IC50 is 0.08 nM. PROTAC FGFR2 degrader 1 has anti-proliferative activity and highly selective, induces G0/G1 arrest of KATOIII and SNU16 cell cycle and inhibits apoptosis by reducing the activation of p-ERK and p-PLCγ, the downstream proteins of FGFR2. PROTAC FGFR2 degrader 1 inhibits gastric cancer cells remained above 50% at a concentration of 0.17 nM. PROTAC FGFR2 degrader 1 potently inhibits the growth of SNU16 xenograft tumors in mouse model (Structure Note: Pink, FGFR2 activator: HY-18708; Blue, E3 ligase ligand: HY--10984; Black, linker: HY-163989; E3 ligase ligand + linker:HY-163986) [1].
    PROTAC FGFR2 degrader 1
  • HY-N2209

    PPAR Metabolic Disease
    Angeloylgomisin H, as a major lignin extract of Schisandra rubriflora, has the potential to improve insulin-stimulated glucose uptake by activating PPAR-γ .
    Angeloylgomisin H

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: